“More research is needed” are words that you will find written at the end of most scientific research articles.
You will probably hear it a lot if you are talking about using cannabis as medicine.
The American Academy of Neurology (AAN) recently echoed these words, along with a position statement and a request for the RECLASSIFICATION of marijuana as a Schedule I drug.
Currently research is restricted by a big ROADBLOCK which has to be removed. It is the (mis)classification of marijuana as a SCHEDULE I drug—a classification which is supposed to be for drugs that have NO medicinal value.
This severely limits who can conduct research and who gets to have access to the government’s supply of marijuana.
The AAN announced that they “support all efforts to conduct rigorous research to evaluate the long-term safety and effectiveness of marijuana-based products”.
And they added: “The AAN, for research purposes, requests the reclassification of marijuana-based products from their current Schedule 1 status so as to improve access for study of marijuana or cannabinoids under IRB-approved research protocols”.
WHAT ABOUT MULTIPLE SCLEROSIS?
While others are still saying “More research is needed”, The American Academy of Neurology (AAN) has gone ahead with making recommendations to physicians on the use of–certain forms of–cannabis products to treat qualifying multiple sclerosis (MS) patients. They also have a patient guide.
And, MS is one of the approved conditions in many medical marijuana programs, in many states including Hawaii.
UNITED STATES PATENTS on CANNABIS
Enough research has been done that the United States Government has multiple patents on cannabis as a therapeutic agent. One is a 2003 patent of cannabis as a neuroprotectant. And there are more than 80 other U.S. patent (or applications for patents) HERE.
And the Good News is that More US. research is coming!
In December of 2014 the state Colorado health officials awarded $8 million in research grants on to study the use of medical marijuana in the treatment of symptoms associated with Parkinson’s disease, childhood epilepsy and post-traumatic stress disorder.
While we welcome more research and wait for it,
we can follow ongoing research in Israel—
The world leader in cannabis research.
DISCLAIMER: The information provided on this Site is for educational purposes only. This article is not intended to provide medical advice, diagnosis or treatment.
Please consult a physician before beginning any treatment program or making any adjustments in your healthcare, diet, and /or lifestyle.
Do not remove yourself from any prescribed medications or treatments without consulting your doctor.